Literature DB >> 31918023

A computational framework and sensitivity analysis for the hormonal treatment of bone.

Muhammad Idrees1, Ayesha Sohail2.   

Abstract

BACKGROUND: Osteoporosis is a bone disease identified by disordering of bone formation and resorption cells. It increases the risk of bone fragility and fracture. Autocrine and paracrine signalling of osteoclasts and osteoblasts plays an important role in the regulation of bone remodelling. Calcitonin is an approved pharmacologic agent for the treatment of osteoporosis.
METHODS: A novel mathematical model comprising the interaction among osteoclasts and osteoblasts cells with intermittent administration of calcitonin has been presented to study the dynamics of osteoporotic bone. The stability of model and sensitivity of parameters are also discussed.
FINDINGS: The population of osteoclastic and osteoblastic cells has been predicted via numerical simulation. The results of Monte Carlo sensitivity analysis are shown via tornado diagram.
INTERPRETATION: It is concluded that intermittent administration of calcitonin is an effective therapy for the treatment of osteoporosis.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Bone remodelling; Calcitonin; Intermittent therapy; Osteoporosis

Mesh:

Substances:

Year:  2019        PMID: 31918023     DOI: 10.1016/j.clinbiomech.2019.12.015

Source DB:  PubMed          Journal:  Clin Biomech (Bristol, Avon)        ISSN: 0268-0033            Impact factor:   2.063


  2 in total

1.  Piecewise differentiation of the fractional order CAR-T cells-SARS-2 virus model.

Authors:  Ayesha Sohail; Zhenhua Yu; Robia Arif; Alessandro Nutini; Taher A Nofal
Journal:  Results Phys       Date:  2021-12-24       Impact factor: 4.476

2.  Forecasting of the efficiency of monoclonal therapy in the treatment of CoViD-19 induced by the Omicron variant of SARS-CoV2.

Authors:  Alessandro Nutini; Juan Zhang; Ayesha Sohail; Robia Arif; Taher A Nofal
Journal:  Results Phys       Date:  2022-02-26       Impact factor: 4.476

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.